The Other Prescription Drug Problem: Sedative-Hypnotics
Learning Objectives
As a result of participating in this lecture learners should have a working knowledge of the following topics, essential to competency in addiction medicine and identify areas where more study may be needed:
- Epidemiology, to include trends, prevalence/patters of abuse, special populations;
- Pharmacodynamics including drug metabolism and principles of drug interactions; tolerance and cross-tolerance; neurobiology and receptor pharmacology
- Medical assessment and treatment, to include physical signs of acute use, intoxication, withdrawal, delirium; medical emergencies associated with (respiratory function, suicide attempts); management of intoxication and withdrawal
- Office-based screening
- Sequelae of long-term use (cognitive effects, driving, falls, etc.)
- Treatment, including pharmacological interventions to support recovery; self-help and peer group approaches and resources; and evidence-based complementary/alternative health approaches
Richard Ries, MD
Dr. Richard Ries is Professor of Psychiatry at the University of Washington Medical School in Seattle, Washington. Dr. Ries serves as Associate Director of the University of Washington Addiction Psychiatry Residency Program. Dr. Ries is Director of Outpatient Psychiatry, Dual Disorder Programs, and the Chemical Dependency Project at Harborview Medical Center. He is director of substance abuse education at the University of Washington Medical School and director of the Division of Addictions for the Department of Psychiatry. He has obtained NIDA sponsored clinical research grants in 1989 and 1997 to evaluate treatment outcome in dual disorders and also helped develop and participate in a NIDA sponsored training videotape (1996) on dual disorders. Dr. Ries was chosen to chair the first official Treatment Improvement Protocol (TIP#9-1994) on dual disorders by the Center for Substance Abuse Treatment. He is the co-editor of the key reference text Principles of Addiction Medicine, published by the American Society of Addiction Medicine.
Dr. Ries is on the Speakers Bureau for Alkermes Pharma, Janssen Pharma, and Reckitt Benckiser
Available Credit
- 1.00 AAPA
- 1.00 AMA Category 1
- 1.00 CAADAC
- 1.00 California Board of Behavioral Sciences
- 1.00 NCCAP